Comprehensive Guide to Purchasing and Using Platinib

Pralsetinib (English name: Pralsetinib), trade name Pujihua, is a highly efficient and highly selective RET inhibitor targeted drug jointly developed by Blueprint Medicines and CStone Pharmaceuticals of China. The drug was approved by the FDA in 2020 and is mainly used to treat RET gene fusion-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) and RET-mutant medullary thyroid cancer (MTC).

1. Buying Guide

Platinib is a prescription drug that patients need to purchase and use under the guidance of a doctor. In the Chinese market, the price of the original drug Platinib is relatively high, about 20,000 to 30,000 yuan per box, and it is not included in medical insurance, so patients need to pay for it at their own expense. The purchasing methods are as follows:

1. Hospital pharmacy: Patients can go to the oncology department of a regular hospital and purchase it at the hospital pharmacy with a doctor’s prescription.

2. Large chain pharmacies: Some large chain pharmacies also provide sales services for platinib, but they need to be purchased with a doctor’s prescription.

3. Overseas medical institutions: Patients can purchase generic versions of drugs through overseas medical institutions, such as Platinib produced by Laos Lucius Pharmaceutical Company, which is relatively affordable. However, attention should be paid to choosing an institution with good qualifications to ensure the quality of medicines.

2. User Guide

The use of Platinib must be strictly followed by medical instructions. The following are some precautions for use:

1. Dosage and usage: The recommended dose is400 mg, taken orally once a day on an empty stomach (no food for at least 2 hours before taking, and no food for at least 1 hour after taking). If you miss a dose, you should take it as soon as possible, but do not take additional doses after taking the medicine.

2. Adverse reaction monitoring: Platinib may cause a series of adverse reactions, such as conjunctivitis, dry eye syndrome, nosebleeds, stomatitis, interstitial lung disease, loss of appetite, nausea, vomiting, abnormal liver function, abnormal renal function, diarrhea, etc. Patients need to have regular follow-up visits and report discomfort symptoms to the doctor in a timely manner.

3. Medicine for special groups: Contraindicated for pregnant and lactating women. Patients should use an effective non-hormonal method of contraception during treatment and for 2 weeks after the last dose of platinib. It should not be taken by patients with uncontrolled high blood pressure.

4. Drug interactions: Avoid coadministration with strongCYP3A4 and P-gp inhibitors. If combined use is required, the dosage should be adjusted according to the guidance of your doctor.

In summary, Platinib brings new therapeutic hope to patients with RET gene fusion or mutation cancers. When purchasing and using drugs, patients must follow medical instructions and choose formal channels to ensure drug quality and safety. At the same time, follow up regularly and report discomfort symptoms to the doctor in a timely manner to ensure treatment effectiveness and medication safety.